Application of GW3965 in preparation of drugs treating or preventing hepatitis C

A hepatitis C virus and drug technology, applied in the field of medicine, can solve the problem that there is no application of GW3965 in anti-hepatitis C virus, and achieve the effect of improving the cure rate
CN103054844BInactive Publication Date: 2014-04-30WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
0 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN Ā· China
Patent Type
Patents(China)
Current Assignee / Owner
WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Publication Date
2014-04-30
Estimated Expiration
Not applicable Ā· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses application of GW3965 (3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2, 2)-biphenylethyl)amino]propoxy)phenylacetate hydrochloride) in preparation of drugs treating or preventing hepatitis C virus. A drug without any toxic concentration is chosen for an antiviral experiment, the influence of GW3965 on virus gene duplication is detected, and results show that the small molecule compound has significant antiviral activity and is dose dependent. Then, the GW3965 is employed to treat the hepatitis C pseudovirus system of different gene subtypes, and results show that the compound inhibits the virus entrance link at the early stage of a virus lifecycle. The anti-virus capability of drug combination of GW3965 and other anti-HCV drugs is detected, and results show that the compound has the potential of drug combination with other drugs. GW3965 can inhibit 1a, 1b, and 2a genotype virus entrance, and has broad-spectrum antiviral activity and a novel target, while there is no anti-hepatitis C virus drug with entrance as the target clinically. And drug combination can achieve a good effect.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention belongs to the technical field of medicine, and more specifically relates to a small molecule compound GW3965 (3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-bi Phenylethyl) amino] propoxy] phenylacetic acid hydrochloride) in the preparation of medicines for treating or preventing hepatitis C virus (HCV). Background technique

[0002] Hepatitis C Virus (HCV), discovered in 1989, is the main pathogen causing non-A, non-B hepatitis after blood transfusion. About 170 million people worldwide are currently infected with HCV. HCV infection is distributed worldwide, the infection rate is about 3%, and 3 to 4 million new cases are added every year. According to the serological epidemiological survey data in my country, the positive rate of HCV in the general population is 3.2%. The main routes of transmission of HCV include blood transfusion or blood products, intravenous drug use, sexual contact, and mother-to-child transmiss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More